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Complement in autoimmune inflammatory myopathies, the role of
myositis-associated antibodies, COVID-19 associations, and muscle amyloid
deposits
Marinos C. Dalakasa,b
a
Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA; bUniversity of Athens Medical School, Neuroimmunology Unit,
National and Kapodistrian University, Athens, Greece

ABSTRACT

ARTICLE HISTORY

Introduction: The inflammatory myopathies (IM) have now evolved into distinct subsets requiring
clarification about their immunopathogenesis to guide applications of targeted therapies
Areas covered: Immunohistopathologic criteria of IM with a focus on complement, anti-complement
therapeutics, and other biologic immunotherapies. The COVID19-triggered muscle autoimmunity along
with the correct interpretation of muscle amyloid deposits is discussed.
Expert opinion: The IM, unjustifiably referred as idiopathic, comprise Dermatomyositis (DM), Necrotizing
Autoimmune Myositis (NAM), Anti-synthetase syndrome-overlap myositis (Anti-SS-OM), and Inclusion-BodyMyositis (IBM). In DM, complement activation with MAC-mediated endomysial microvascular destruction
and perifascicular atrophy is the fundamental process, while innate immunity activation factors, INF1
and MxA, sense and secondarily enhance inflammation. Complement participates in muscle fiber
necrosis from any cause and may facilitate muscle-fiber necrosis in NAM but seems unlikely that
myositis-associated antibodies participate in complement-fixing. Accordingly, anti-complement thera
peutics should be prioritized for DM. SARS-CoV-2 can potentially trigger muscle autoimmunity, but
systematic studies are needed as the reported autopsy findings are not clinically relevant. In IBM, tiny
amyloid deposits within muscle fibers are enhanced by inflammatory mediators contributing to
myodegeneration; in contrast, spotty amyloid deposits in the endomysial connective tissue do not
represent ‘amyloid myopathy’ but only have diagnostic value for amyloidosis due to any cause.
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1. Introduction
Inflammatory myopathies (IM) are a heterogeneous group of
acquired myopathies, which, based on distinct clinical, histo
logical, and immunopathological features as well as associa
tion with certain autoantibodies, have evolved into four
distinct
subsets:
Dermatomyositis
(DM),
Necrotizing
Autoimmune Myositis (NAM), or Immune-Mediated Necrotizing
Myopathy (IMNM), Anti-synthetase syndrome-overlap myositis
(Anti-SS-OM), and Inclusion-Body-Myositis (IBM) [1,2]. As
recently stated by Tanboon et al., the clinicopathological clas
sification of IM, as first introduced 30 years ago [3,4], had also
included Polymyositis (PM), even if we have repeatedly stated
for many years that it is a very rare disease subtype. It has now
become more clear that PM is not only rare but may not exist
as an isolated entity; because it may very rarely seen in asso
ciation with another autoimmune systemic or viral disease it
has been included in the classification of IM mostly for histor
ical reasons [1]. As continuously witnessed by many authors in
the last 15 years, patients referred to experienced centers for
PM they either have IBM, NAM, or an inflammatory dystrophy
[1–7]. Each of the four IM subsets has distinct clinical features,
pathomechanisms, prognosis, and response to therapies,
requiring careful clinicopathologic correlations with expertise
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not only in clinical neuromuscular diseases but concurrently in
muscle histopathology and immunopathology to exclude dis
ease mimics.
This article briefly describes the main clinicopathologic
and immune features of each IM subtype, but it is mostly
focused on the role of complement in facilitating necrosis
within the muscle tissue, predominantly in DM and NAM.
The main reason for such a focus is to stimulate interest
considering the exciting success of anti-complement thera
peutics in other autoimmune neurological diseases where
complement plays a role such as Myasthenia gravis and
Neuromyelitis (NMO-SD). Within the pathogenetic mechan
isms of all IMs, reference is made on the significance of
amyloid muscle deposits and on COVID19-triggered immu
nopathology. These are discussed because amyloid is seen
within the muscle fibers in IBM and viruses have been
implicated as triggering factors in IM, but both issues
need clarification due to recent rather confusing reports to
avoid misinterpretations in reference to their significance in
the field of IM. Further, anti-complement therapeutics may
have a beneficial effect on COVID-associated conditions, as
discussed later, hence their relevance in the treatment of IM
during the COVID19 pandemic.
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The inflammatory myopathies are not “idiopathic” as unjustifiably
have been currently referred. They comprise four distinct subsets:
Dermatomyositis (DM), Necrotizing Autoimmune Myositis (NAM), Antisynthetase syndrome-overlap myositis (Anti-SS-OM), and Inclusion-BodyMyositis (IBM).
The fundamental mechanism in DM is complement activation and
MAC-mediated microvasculopathy that lead to ischemia and perifas
cicular atrophy, and not interferon os secondary elements of innate
immunity as some believe. Anti-complement agents targeting C3-C5
may lead to sustained clinical remission and should be explored in
controlled trials.
There is strong evidence that SARS-CoV-2 does not infect muscle
fibers but, like any other virus, has the potential to trigger muscle
autoimmunity but this remains to be explored as findings from
autopsy cases are unconvincing and clinically irrelevant. Prospective
studies with clinicopathologic correlations are needed.
Spotty amyloid deposits in the endomysial connective tissue do not
represent ‘amyloid myopathy’ as recently stated, but they only have
diagnostic value to detect amyloidosis due to any cause, neuropathic,
systemic, or hereditary.
Biologic agents targeting FcRn should be explored as potential ther
apeutic agents in DM, NAM, and anti-SS-OM

2. Clinicopathologic characteristics,
immunopathology, and role of complement
2.1. General clinical principles
Patients with all IM subtypes experience slow, subacute,
and rarely acute-onset of muscle weakness mostly in

proximal muscles, such as climbing steps, getting up
from a chair or raising arms, as seen in all subtypes except
for IBM which may often present first with distal muscle
weakness in hands and feet with difficulties making a grip,
typing, or raising the feet and legs [1–9]. Weakness in the
neck-extensor muscles can be prominent, resulting in head
drop or difficulty holding up the head; dysphagia can be
seen in all IM subsets. In some clinically advanced cases,
respiratory muscles are also affected. Myalgia and muscle
tenderness are features in all IM subsets, but they are
especially prominent in anti-SS-OM. Extramuscular manifes
tations such as arthralgia, Raynaud’s phenomenon, and
pulmonary complications due to interstitial lung disease
are frequent in anti-SS-OM and amyopathic DM with antiMDA-5 [Melanoma Differentiation-Associated protein-5]
antibodies [1–7,9,10]. Up to 75% of all IM patients have
various autoantibodies directed against nuclear RNAs or
cytoplasmic antigens, which although nonpathogenic, can
be associated with distinct clinical phenotypes aiding in
the classification or diagnosis. The clinico-immuopathology
of each of the four main IM subsets and the role of
complement is as follows..

2.2. Dermatomyositis (DM)
2.2.1. Clinicopathology
Patients with DM manifest characteristic skin changes consist
ing of periorbital blue-purple discoloration, an erythematous

Figure 1. Complement activation leads to microvascular and perifascicular damage, that triggers inflammation sensed by innate immunity factors (INF1, MxA) which
secondarily enhance the local immune response [modified from [1,7]].
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rash on the face but also on the neck, anterior chest, and
shoulders, and a violaceous eruption (Gottron’s rash) at the
knuckles. Skin changes precede or accompany proximal mus
cle weakness. In a small patient subset, the disease is clinically
limited to the skin, referred to as ‘amyopathic dermatomyosi
tis,’ because they have normal strength [11]; their muscle
biopsies, however, always show subclinical inflammatory myo
pathic features [1,7]. Cracked palmar fingertips (‘mechanic’s
hands’) are characteristic along with dilation of the capillary
loops at the base of the fingernails. The symptoms of
Dermatomyositis may overlap with mixed connective tissue
disease, systemic sclerosis, and with the anti-synthetase syn
drome-overlap myositis (anti-SS-OM) [1,2,7]. The muscle
biopsy shows inflammation, predominantly around the blood
vessels (perivascularly) or in the interfascicular septae and the
periphery of the fascicles, with necrosis and phagocytosis due
to microinfarcts that lead to hypoperfusion and layers of
atrophic fibers at the periphery of the fascicle referred to as
perifascicular atrophy [1–7] [Figure 1, as modified from [1,7]]
In patients with active disease, the serum Creatine Kinase is
elevated but it may at times be normal reflecting the predo
minance of the pathology in the interstitial connective tissue.
In 15% of adults with DM, there is a malignancy risk the first 3–
5 years from disease onset [1,12]. Certain Dermatomyositisassociated antibodies may be connected with a specific DM
subtype. Specifically, antibodies against (a) Mi-2, highlight
typical skin lesions; (b) melanoma differentiation–associated
protein-5 (MDA-5) are mostly connected with amyopathic
DM or with interstitial lung disease; and (c) transcriptional
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intermediary factor-1 (TIF-1) and nuclear matrix protein NXP2, are likely connected with cancer-associated DM [1,2,6,13].

2.2.2. Role of complement in the immunopathology of
Dermatomyositis
In DM, the endothelium of the capillaries is primarily targeted
by C5b-9 Membranolytic Attack Complex (MAC) which is
deposited on the endothelial cells early in the disease and
before any evident muscle fiber destruction [1–7,14–16]. The
complement deposits cause endothelial cell necrosis and
reduction of the endomysial capillaries leading to ischemia
and micro infarcts especially at the periphery of the fascicles
explaining the noted perifascicular atrophy; the remaining
capillaries have dilated lumens probably in an effort to com
pensate for the ischemic process [1–7] (Figure 1). The MAC
activation triggers the release of proinflammatory cytokines,
up-regulation of adhesion molecules on endothelial cells and
migration into the endomysium of activated CD4 + T-cells,
macrophages, B cells, and CD123+ plasmacytoid dendritic
cells [1].
How does the activation of the lytic complement pathway
takes place remains unclear. Evidence suggests a direct C1qmediated CP (Classical Pathway) activation process by the
diseased endothelium because C1q and C4 are deposited
early in the disease in the proximity to C5b-9 without con
current Immunoglobulin IgG deposits [16–19]. Whether MAC
deposition on the endomysial capillaries is the consequence of
low CD59 expression or low levels of circulating vitronectin
and clusterin enabling an innocent bystander process, remains

Figure 2. Interception of complement by IVIg in Dermatomyositis leads to restoration of histological picture and clinical improvement [modified from [23,24]].
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a theoretical but never explored possibility [17–19]. Innate
immunity also plays a secondary role, as evidenced by the
increased expression of type-I interferon-inducible proteins in
the perifascicular regions [20]; such an effect is, however,
secondary to inflammatory ischemic damage, which is sensed
by the retinoic acid-inducible gene-1 signaling leading to
auto-amplification of local inflammation by activating βinterferon and MHC-1, as discussed [21], enhancing further
the local complement-triggered inflammation.
In spite of the uncertain events that trigger complement
activation, the primary event in DM is unambiguously
a complement – mediated microangiopathy because inhibi
tion of C3b by IVIg results not only in interception of MAC
assembly in the patients’ tissues but also in significant clinical
improvement, resolution of histopathological changes and
disappearance of MAC from the muscle fibers (1,3,7), as clearly
depicted in Figure 2 and explained below.

2.2.3. Key observations on complement and inflammatory
molecules in DM based on the effects of IVIg
IVIg, comprised of IgG immunoglobulin molecules from a pool
of thousand donors, binds C1q effectively preventing patho
genic antibodies from triggering the complement cascade; it
also binds activated C3 and C4 inhibiting their tissue deposi
tion [22,23] [#1 in Figure 2 as modified from [23,24]]. The
most convincing in vivo and in vitro example of the efficacy of
IVIg via complement inhibition is the double-blind, placebocontrolled study in patients with treatment-resistant dermato
myositis, which has clearly shown that IVIg is clinically effec
tive by inhibiting complement at the C3 level [24]. Based on
this pivotal study conducted 30 years ago, IVIg rapidly forms
complexes with C3b, inhibits C3 consumption as early as
2 days after infusion, and intercepts MAC formation in the
patients’ muscles by reducing the assembly of C5 convertase
[19,23] [#2 in Figure 2, as modified from [23,24]]. These
effects were shown in the serum of DM patients randomized
to IVIg and their repeated muscle biopsies in correlation with
the clinical improvement [23,24]. IVIg exerted an impressive
and statistically significant clinical benefit compared to pla
cebo-randomized patients, leading after three monthly infu
sions to normalization of their muscle strength and

elimination not only of the active violaceous skin rash but
also of the chronic scaly skin eruptions [24]. Based on repeated
muscle biopsies from the improved patients, IVIg inhibited
MAC deposits from the endomysial capillaries by intercepting
the incorporation of C3 into the C5 convertase assembly
resulting in resolution of the destructive histological changes
with reversal of the atrophic muscle fibers and improved
microvasulatute due to neovascularization [23] [#3 in
Figure 2: a,c,e before therapy compared, respectively,
with b,d,f, as modified from [23,24]]. By inhibiting comple
ment, IVIg also eliminated the endomysial inflammatory cells
and downregulated key cytokines and adhesion molecules
including the overexpression of the intercellular adhesion
molecule (ICAM-I) on the endomysial capillaries, the major
histocompatibility complex class I (MHC-I) antigen on muscle
fibers, and the TGF-β1 in the connective tissue, both at the
protein and mRNA level [25]. IVIg also modified certain immu
noregulatory and structural genes based on gene array studies
in the repeated muscles of DM patients who improved after
IVIg therapy, with upregulation of the expression of the che
mokine Mig/CXCL9 gene and reduction of anosmin-1/KAL-1
gene, which encodes a protein involved in fibrosis or tissue
remodeling clinically correlating with reduced of longstanding fibrosis in the muscle and the skin lesions [26].

2.3. Necrotizing autoimmune myositis (NAM) or
immune-mediated necrotizing myopathy (IMNM)
2.3.1. Clinicopathology
NAM—a term more preferable and euphonic than the com
monly used IMNM—has now evolved as one of the most
common IM subtype [1,2,7]. It may have an acute onset, reach
ing its peak over days or weeks or a steadily progressive
course over weeks or months causing severe weakness and
very high creatine kinase (CK) levels. NAM may also occur after
viral infections and in association with cancer or immune
check point inhibitors [1,2,27]; it has been, however, often,
although non-convincingly, attributed to statins or overdiagnosed as a ‘statin-myopathy’ in patients on chronic statin
administration [28], even though the evidence has been per
ipheral [29,30]. Acute rhabdomyolysis, as prominently seen in

Figure 3. Main histopathological features of Necrotizing Autoimmune Myositis characterized by necrotic fibers (a, b) invaded by macrophages (c), that exhibit spotty
MHC-I expression (d) [modified from [1]].
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NAM, can very rarely coincide with the initiation of statin
therapy, which is implicated as the causative factor in rare
cases of acute-onset NAM, but there is no direct and convin
cing evidence supporting the view that statins play a role in
suddenly triggering NAM or worsening a preexisting myopa
thy in patients who have been taking statins for years [1,29–
33]. The most characteristic histological finding in NAM is the
abundance of necrotic fibers invaded or surrounded by macro
phages; MHC-I upregulation mostly in the necrotic fibers is
common but lymphocytic infiltrates are sparse [1,2,7], as
depicted in Figure 3 [modified from [1]]. In a number of
muscle biopsies there is deposition of complement on the
necrotic muscle fibers and occasionally on some blood vessels
[1,2,9,28,29].

2.3.2. Necrotizing autoimmune myositis-specific
antibodies and role of statins
Two antibodies, one directed against the translational trans
port protein SRP (Signal Recognition Particle) and another
against a 100-kd autoantigen identified as HMGCR
(3-hydroxy-3-methylglutaryl-coenzyme A reductase) are seen
in up to 65% of NAM patients [1,2,9,28–31]. These are impor
tant disease markers, but whether they are pathogenic, as
proposed [28,32], remains unclear. Since HMGCR is the phar
macological target of statins which can upregulate HMGCR in
myotubular cells in tissue cultures [28], anti- HMGCR antibo
dies have been considered associated with prior statin use.
Although this is a very logical hypothesis, in reality these
antibodies have been most often observed in statin-naive
patients and more commonly in patients with malignancies
rather than those taking statins [9,27,33,34]. Arguably, a very
small number of patients early on when statins are initiated
may experience transient myalgia, and others transient CK
elevation but no overt muscle weakness. If myalgia persists,
it is a sign of statin intolerance as seen in some patients. The
implication, however, that chronic statin administration can, all
of a sudden, trigger what is labeled as ‘statin-myopathy’ in the
form of NAM with antibodies against HMGCR, a ubiquitous
and non-muscle-specific antigen, has not been substantiated
[33,34]. Since NAM is now the commonest inflammatory myo
pathy and more than 25% of Americans above the age of 40
are prescribed statins, the noted association between statins
and NAM is likely a chance phenomenon [1,34]

2.3.3. Role of complement in NAM
Because in NAM, in addition to the antibodies, there are
necrotic fibers, CD68+ macrophages in the endomysium, and
spotty MHC-I expression with complement deposition as
depicted in Figure 3, a complement-mediated cytotoxicity
with the recruited macrophages representing an antibodydependent cell-mediated cytotoxicity (ADCC) has been pro
posed [32]. Although this may seem a reasonable hypothesis,
the evidence implicating the complement-dependent patho
genic role of these antibodies via an ADCC mechanism is very
weak and unconvincing. Both, SRP and HMGCR, are antibodies
directed against non-muscle-specific antigens localized in the
endoplasmic reticulum and are highly unlikely immunopathlo
gically that antibodies against such ubiquitous cytoplasmic
antigens can selectively target muscle fibers and cause cell
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necrosis [31,33,34]. Most importantly, classic muscle immuno
pathology studies have shown that the expression of MHC-1
and the deposits of C5b-9 complement are always observed in
necrotic and regenerating fibers due to any cause including
nonimmune myopathies [35,36]; in muscular dystrophies for
example, the necrotic fibers unambiguously activate comple
ment, which in turn stimulates cellular infiltrates and macro
phages [35,36]. Further, the argument that the anti-SRP and
HMGCR antibodies can cause atrophy in myotubular cultures
[37] is irrelevant to the pathogenesis of NAM, which is char
acterized by abundant muscle fiber necrosis and devastating
muscle fiber destruction, not by nonspecific muscle fiber atro
phy. The observations that C1q can be present in the proxi
mity to the sarcolemma alongside IgG deposits and that some
scattered necrotic muscle fibers show C5b-9 sarcolemmal
deposits [32] may seem compelling regarding involvement
of the CP pathway in myofiber necrosis; we need, however,
to be cognizant and objectively recognize that such comple
ment activation is inherently associated with muscle fiber
necrosis from any cause and do not denote specificity in the
immunopathogenesis of NAM. Our concerns and reservations
that we have repeatedly expressed since 4 years ago [31,33,34]
about the pathogenicity of complement interpretation in NAM
proposed by Allenbach et al. [32] are now justified. In a phase
2, randomized, placebo-controlled clinical trial, zilucoplan,
a monoclonal antibody against complement C5, did not have
significant clinical effects in patients with NAM, and the study
was prematurely terminated [ClinicalTrials.gov identifier:
NCT04025632]. Patients with NAM based on small open-label
series but also in our experience respond very well to IVIg, but
this benefit is likely unrelated to complement inhibition but
likely due to other immunomodulatory effects exerted by IVIg.

2.4. Anti-synthetase syndrome-overlap myositis
(Anti-SS-OM)
These patients present with systemic sclerosis-like lesions,
mild-to-moderate proximal muscle weakness, interstitial lung
disease, arthritic changes in the form of subluxation of the
interphalangeal joints and ‘mechanic’s hands’ [1,2,7]. The antiSS-OM syndrome is characterized by the presence of antibo
dies against anti-synthetase, primarily anti-Jo-1; hence, the
naming ‘anti-Jo-1 syndrome’ that dates back to 30 years ago
[38]. These patients seem to also have necrotizing features
including CD68+ cells in the perimysium and perifascicular
muscle fibers [2,39] but also CD3+ lymphocytes, with the
histological signs overlapping those of DM; whether anti-SSOM is a histologically distinct entity with necrotizing features
in the perimysial and perifascicular areas different from the
perifascicular lesions seen in DM, as suggested based in small
series [2], remains a reasonable possibility that requires careful
clinicohistologic confirmation. Antibodies against aminoacyltRNA synthetases, are detected in 20–30% of these patients
[1,2,5,7], with most common the one directed against the
histidyl-transfer RNA synthetase (anti-Jo-1) which accounts
for 75% of all the anti-synthetases and defines the ‘antisynthetase- syndrome.’ The pathogenic role of these antibo
dies, which are directed against ubiquitous cytoplasmic anti
gens, remains uncertain. Because in anti-SS-OM there is
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necrosis in the perifascicular areas that presumably implicate
complement activation, this subset may theoretically be
amenable to anti-C3 or C5 anti-complement therapeutics.

2.5. Inclusion body myositis (IBM)
IBM is the most common inflammatory myopathy in patients
above the age of 50. It is also the most disabling because it
responds poorly to all available therapies and experimentally
performed clinical trials [1–7]. The disease starts slowly, over
years, rather insidiously and often asymmetrically with weak
ness and atrophy, either in distal upper extremity muscles,
such as finger flexors with forearm atrophy, or the lower
extremities with quadriceps muscle weakness and frequent
falls due buckling of the knees; mild facial muscle weakness
and dysphagia are also seen in more than 50% of the patients
[1,3–7,40,41].
Inclusion-body myositis is a complex disorder because
autoimmunity co-exists with myodegeneration [1,7,41,42].
CD8+cytotoxic T-cells not only surround but also invade
healthy, non-necrotic muscle fibers, which aberrantly express
MHC-I, probably induced by T-cell-activated cytokines; the
CD8/MHC-I complex is characteristic of IBM aiding in the
histological diagnosis [1,3–7,41–44]. Plasma cells and myeloid
dendritic cells are also seen among the endomysial infiltrates,
while nonspecific anti-cytosolic 5’-nucleotidase- 1A (cN1A),
detected in 33–51% of IBM patients, highlight the immune
dysregulation and B-cell activation [1,3–7,41–45]. The evidence
of degeneration is highlighted by the presence of autophagic
vacuoles with bluish-red material, proteinacious aggregates
positive for ubiquitin, tau and TDP43 and congophilic amyloid

deposits within the muscle fibers next to the vacuoles, visua
lized best with crystal violet or fluorescent optics as shown in
Figure 4(a) [as modified from [1]]; chronic myopathic
changes with atrophy and increased connective tissue as
well as ‘ragged-red’ or cytochrome oxidase–negative fibers
due to abnormal mitochondria, are also frequent [1,3–7,41–
46]. The co-existence of degeneration and autoimmunity has
been the impetus to study their interrelationship. MHC-1 or
nitric oxide-induced cell stress along with long-standing proin
flammatory cytokines, like interferon-γ and IL1-β, can cumula
tively enhance degeneration with further accumulation of
stressor molecules, misfolded proteins, and amyloid deposits
leading to further disease progression with muscle atrophy
and myofiber loss [1,7,10,42–48].

2.5.1. Muscle Amyloid and Neuroinflammation in IBM with
comments on the recent label ‘Amyloid-Myopathy’
In IBM, bAPP amyloid is deposited within the muscle fibers
along with other misfolded protein aggregates; their accumu
lation along with autophagy seem enhanced by chronic T-cellmediated cytotoxicity molecules and pro-inflammatory cyto
kines, such as IFN and IL1b [47–50]. On this basis, immuno
suppressive agents have been tried in IBM but all failed
probably because the degenerative cascade starts insidiously
very early in the disease process, being already advanced
when patients seek medical advice [1,7,10,47–52]. More speci
fically, the pivotal controlled studies with IVIg and steroids
were statistically negative [53,54], while the highly scholarly
trial with Alemtuzumab targeting activated T cells but also
B cells showed clear but small benefits [55] requiting a larger
trial.

Figure 4. Amyloid deposits within muscle fibers in IBM (a) [modified from [1]]. Amyloid in the connective muscle tissue (b,c) is seen in all kinds of amyloidosis, from
neuropathies (b) to systemic (c) and only has diagnostic value [modified from [51,60,61]].
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Amyloid can be seen within the muscle fibers not only in
IBM, as depicted in Figure 4a, but also in several chronic
vacuolar myopathies, dystrophies, even in chronic neurogenic
conditions, like post-polio syndrome [56]; it does not however
denote ‘amyloid myopathy’ as recently suggested even stating
‘unmasking the master of disguise’ [57–59]. Apart from such
amyloid deposits inside the muscle fibers connected to dis
ease chronicity or neuroinflammation, small or spotty amyloid
deposits outside the muscle fibers in the interstitial connective
muscle tissue, the perimysium, or around muscle fibers have
been repeatedly observed in the patients with amyloid neu
ropathies, either TTR (Figure 4(b)) or plasma cell dyscrasia
(Figure 4 (c)) [modified from [51,60,61]], more than 30 years
ago [60–62]. In pivotal studies on a large number of amyloid
neuropathy patients, such connective tissue amyloid deposits
were of diagnostic, but not of pathogenic significance, and
clearly not constituting ‘amyloid myopathy’ as recently pro
posed [57–59,63]. In a large number of patients with poly
neuropathies, the muscle biopsy had a high diagnostic yield
for detecting amyloidosis, even more than a nerve biopsy or
the abdominal fat [60–62]. In these studies, among patients
with various neuropathies, amyloid was detected in the endo
mysial connective tissue in at least 39 studied patients, con
cluding that the muscle is not only an excellent tissue to
search for generalized amyloidosis due to any cause, such as
kidney, heart, plasma-cell dyscrasia, and genetic (TTR) or
sporadic amyloid neuropathies but also a useful source to
identify, extract and characterize the type of amyloid with
biochemistry and immunocytochemistry using antibodies
against light chains, AA, or transthyretin as previously done
[60,61]. These amyloid deposits have the same diagnostic
value, as very recently shown for the skin in amyloid neuro
pathies [64] The mere presence of amyloid speckles in the
connective tissue or decorating the periphery of muscle fibers,
as depicted in Figure 4(b,c), does not by any means fulfill
clinicopathologic criteria of myopathy and does not clearly
represent myopathy; naming them recently as ‘amyloid myo
pathy’ based on very few specimens [57–59,63] is not correct.
Amyloid deposits are also unrelated to complement. In IBM,
there may be areas of complement deposits in rare necrotic
muscle fibers associated with the necrotic process as dis
cussed earlier, but not within the vacuolated or amyloidpositive fibers to justify consideration for anti-complement
therapies.

3. SARS-CoV-2 as a potential trigger of IM and role
of anti-Complement immunotherapies
The connection of viruses as possible triggers of IM-known for
many years [65]- has become timely during the COVID19
pandemic. Because viruses have the potential to break toler
ance, they can trigger an immune inflammatory myopathy
during or after the infection [1,7,65]. Several attempts, how
ever, to amplify a variety of common viruses, including para
myxoviruses, mumps, coxsackieviruses, influenza, cytome
galovirus, and Epstein–Barr virus, from the muscles of patients
with IM have all failed [65]. Perhaps, the best studied viral
connection has been with retroviruses in patients infected
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with HIV or Human-T–cell-lymphotropic Virus-I who developed
IM including IBM [1,7,66–69]. In a number of such specimens,
retroviral antigens were detected not within the muscle par
enchyma but only within some endomysial macrophages
(Trojan-horse mode); further, several autoinvasive T cells
were clonally driven or retroviral-specific [68]. During the
COVID19 pandemic, there has been evidence that some
COVID19-infected patients develop multifactorial myalgia
and weakness even elevated CK suggestive of an inflamma
tory myopathy similar to HIV-assocted cases [69]; there has not
yet been, however, a convincing clinicopathological series of
IM in COVID19-infected patients except of rare case reports
[70,71].
Two large series entirely on muscle-autopsied specimens
from ICU-hospitalized patients who died from SARS-CoV-2,
have now reported lymphocytic infiltrates and a few scat
tered MHC-1-positive muscle fibers in up to 55% of the
examined specimens [72,73]. Other histological but nonspe
cific features included capillary expression of human myxo
virus resistance protein MxA, some NK cells and occasional
MAC deposits which however were also seen in SARS-CoV
-2-negative ICU controls. Although there was absolutely no
clinical information to support myositis, these nonspecific
autopsy histological observations were interpreted as
COVID-19-postinfectious-immune-mediated myositis [72].
MHC-1 upregulation can be seen in necrotic or regenerating
muscle fibers from any cause, including muscular dystrophies
[74]; further, active viruses, like HIV/HTLV-1, strongly upregu
late MHC-I even on normal muscle fibers in asymptomatic
individuals [69]. In an aggressive viral disease like SARS-CoV
-2, where cytokines and inflammatory mediators are abun
dant, scarcely observed lymphoid cells are non-musclespecific and can be seen in any tissue, as observed in autop
sied hearts, nerves, and muscles without clinical myocarditis,
neuritis, or myositis [75]. Like any other virus, SARS-CoV-2 has
however the potential to trigger myositis, as some rare anec
dotal cases suggest [71], but we still need to identify it and
define the inflammatory myopathy subtype, along with its
frequency and mechanism [75]. The reports from autopsy
patients with long-standing weakness due to critical illness
neuromyopathy do not provide direct evidence of viralrelated myositis; a SARS-CoV-2-myositis should be investi
gated in infected patients who present with muscle weak
ness and elevated CK. Although these autopsy series, in spite
of the reported claims, did not show myositis in people who
have died from COVID19 [75], they did show that nonspecific
inflammatory cells can be seen in any tissue of SARS-CoV-2
patients early in the disease due to abundant cytokines and
inflammatory mediators. Physicians should be therefore care
ful not to overdiagnose them as tissue-specific inflammatory
or autoimmune disease processes [75]. These autopsy series
did convincingly, however, show that SARS-CoV-2, although
detectable in the lung tissue, was not found in muscle and
did not infect muscle fibers [72,73], which was not- unex
pected because no viruses, temporally implicated in viraltriggered myositis, have been up to now detected in muscle
or have been shown to infect muscle tissue based on
detailed molecular studies [65–69]. Instead, viruses, as con
vincingly shown with HIV early in that epidemic, can induce
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T-cell mediated-cytotoxicity or viral-specific T cells and
macrophages that invade muscle fibers without infecting
the muscle [1–4,7,66–69,75]. Reports claiming immunohisto
chemical viral stains or viral-like particles in muscles from ICU
patients with severe histological myopathic changes should
be viewed with caution.

3.1. Complement and COVID19
Since complement is an integral component of the innate
immune response to common viruses, activation of C3 can
worsen the COVID-19- associated acute respiratory distress
syndrome; as a result, abundant complement deposits can
be seen in the lung biopsies of SARS-CoV-2-infected patients
[76,77]. On this basis, anti-complement therapies are consid
ered as having potential beneficial effects in COVID-19infected patients and trials with ravulizumab and eculizumab
are currently ongoing [78–80]. In relevance to IM, the clinical
importance of this concept applies to patients with DM or
NAM where complement plays a role in their pathomechan
ism. If such patients are infected with COVID-19, very appro
priate questions have been raised as to whether anticomplement therapeutics, like a trial with eculizumab, have
the potential to exert a protective effect against severe disease
worsening or even being a preferable means in treating such
rare events [19].

4. Present treatment algorithm for DM, NAM,
anti-SS-OM
For patients with DM, NAM and anti-SS-OM, prednisone
remains the first-line drug based on experience but not con
trolled studies. As steroid-sparing agents, mycophenolate is
our preferred agent, but others choose Azathioprine or
Methotrexate. If frequent relapses occur or the response to
steroids is not satisfactory or not well tolerated, IVIg is the best
choice, especially in DM based on the strongly positive con
trolled study [24]; further, IVIg is now FDA-approved for DM. If
steroids and IVIg are insufficiently effective, proceed to biolo
gics with the primary one rituximab which, in our experience,
has been very helpful in many of our tested patients. Among
new agents, the biologics against complement (i.e.
Eculizumab), IL-6 (Tocilizumab), CD20/CD19 monoclonals, or
FcRn inhibitors like Efgartigimod should be investigated in
controlled studies [81,82]

5. Expert opinion
The field of Inflammatory myopathies, comprised of disorders
originally described by neurologists, has tremendously
advanced for 3 decades, from 1980 to 2010, thanks to enor
mous contributions of Neuromuscular Neurology scholars
who, by combining clinical expertise with neuromuscular
pathology and immunopathology, recognized distinct disease
subtypes, precisely defined their clinicopathological criteria,
and performed pivotal clinical trials, such as the successful
IVIg trial in Dermatomyositis [24]. Over the last decade, the
field is gradually changing hands and direction. Neurologists

with muscle pathology and immunopathology training
become increasingly scarce with exceptionally few still per
forming or processing their own patients’ muscle biopsies in
their own muscle enzyme histochemistry laboratories, as their
former scholars and mentors did. Today most clinicians
involved in the diagnosis and care of IM patients have differ
ent training backgrounds, comprised mostly by rheumatolo
gists, internists, neurorheumatologists, or neurologists/
elctromyographers; muscle biopsies are now performed by
surgeons, read by pathologists on paraffin sections or with
elementary enzyme histochemistry and immunopathology
stains and without clinicopathologic assessments or correla
tions. This disconnection has changed the philosophy of the
IM field; the former neuromuscular scholars when looking at
their patients’ muscle biopsies had the patient’s symptoms in
mind, thinking of the diagnostic possibilities and therapies,
like looking their muscles in vivo. The focus has now steadily
shifted; muscle-associated antibodies (called ‘myositis-specific,
’ even if nonpathogenic), muscle imaging, and new clinical
phenomenology are leading the way in establishing new
diagnostic and classification criteria among same-minded
groups. There has even been a change in the name to
‘Idiopathic Inflammatory Myopathies’ although it is unclear
what idiopathic refers to. We do not call the rheumatoid
arthritis, scleroderma, Sjogren’s syndrome or multiple sclerosis
‘idiopathic’ although the knowledge of inflammation and
autoimmunity in IM is comparable to the other common
autoimmune diseases.
The impact of not relying anymore on clinicoimmunopathologic correlations is highlighted in the present
review by three issues, the role of complement and autoanti
bodies, viruses and specifically COVID19 in triggering IM, and
the role of muscle amyloid deposits. Complement plays
a major role in muscle fiber necrosis due to any cause includ
ing muscular dystrophies, as highlighted in the classic studies
of Dr Andrew Engel, who convincingly concluded more than
25 years ago that ‘there is no evidence to support a role of
antibody-dependent complement-mediated muscle fiber
injury in the major inflammatory muscle diseases’ [35,36].
These studies have clearly shown that the ingress of specific
C5b9 complement components into muscle fibers activates
the lytic pathway that assembles the MAC, while the chemo
tactic C5a molecule recruits macrophages to the necrotic
fibers. Unfortunately, these classic observations, which are
quite valid today, have been forgotten; a series of recent
studies repeatedly conclude that nonspecific antibodies
against cytoplasmic and ubiquitous antigens are ‘comple
ment-fixing’ because they were found deposited on comple
ment-bearing necrotic fibers [37], not taking into account that
the complement was already there due to ongoing necrosis
and had nothing to do with these antibodies, as now sup
ported by a negative anti-complement study. On the other
hand, the fundamental role of complement in causing micro
angiopathy in dermatomyosits, described by three different
scholarly groups more than 20 years ago [14–19,23,24] is now
viewed as a secondary event because DM is now fancifully
labeled as interferonapathy [reviewed in [2]]. I wonder who
will prefer to treat DM with anti-interferon type-1 agents (if
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exist) instead of IVIg, anti-B cell-targeted therapies, or anticomplement agents, a question especially relevant to DM,
which I strongly consider as the main candidate among all
IM for anti-complement therapies [19]. The lack of clinico
pathological correlations is best exemplified by the interpreta
tion of COVID19-triggered IM. Based only on autopsy samples
from comatose patients who died from a systemic COVIDdisease, pathologists have interpreted nonspecific histological
muscle findings, such as spotty MHC-1 expression and a few
scattered lymphocytic cells, as ‘clinically significant’ [72], an
obvious misinterpretation; it cannot be clinically significant
myopathological findings in comatose patients that died
from a systemic disease without ever having, when alive,
clinical myopathy. During an active viral infection or an
aggressive viral systemic disease, nonspecific inflammatory
cells or MHC-expression can be seen in any tissue due to
release of cytokines and inflammatory mediators, as classically
described in other viral infections even without clinical signs
of myopathy [67–69]. What was reported in these autopsied
muscles has been a rather misleading overinterpretation of
the classic immunopathological features described 40 years
ago by the legends in the field such as George Karpati and
Andrew Engel [43,74]. Another also surprising interpretation is
the tiny amyloid deposits seen in the muscle connective tis
sue. For years, it is known that such amyloid spots in the
connective tissue are only of diagnostic significance, similar
to the abdominal fat biopsy, seen in all types of amyloidosis,
from plasma cell dyscrasic to genetic amyloid neuropathies
[57–59]. These tiny amyloid deposits do not represent ‘amy
loid myopathy’ as recently overinterpreted [54–56]; it is not
pathologically possible that these connective tissue amyloid
dots can cause histological signs of myopathy in patients who
clinically have neuropathy.
This personal view, although critical, is aiming to pinpoint how
the field of IM is now changing and highlight that a comprehensive
expertise and unbiased interpretation of clinicopathological find
ings still remains the best means to advance the field and capitalize
on new therapies. The IM experts should be open-minded to work
together with previous leaders in the field and focus on combining
excellence in the clinic, being able to distinguish functional weak
ness or fatigue from true myopathic weakness caused either by an
IM subtype or inflammatory dystrophy; correctly interpret the
biopsies in conjunction with the clinical features; and appreciate
immunology and molecular immunopathology to apply targetspecific immunotherapies. One cannot envision how a clinician
who is not a neurologist can confidently distinguish muscle weak
ness due to IM from myasthenia, muscular dystrophy, neuropathy
or neuronopathy and interpret the electromyographic findings; or
how an electromyographer can judge the significance of the
circulating antibodies and express a scholarly and critical opinion
in interpreting the immunology and immunopathology; and still
how a general pathologist can appreciate the clinical phenomena
seen in various IM subtypes or offer an opinion in applying targetspecific immunotherapies. The field on immunotherapeutics in IM,
such as anti-complement therapeutics highlighted in this review,
or against FcRn and B cells [80,81] requires such a combined
expertise to select the most suitable targeted therapy in this
arguably complex and heterogeneous group of IM.
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